Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review

Schizophrenia Research

Volumn 168, Issue 3, 2015, Pages 603-613

  Heringa, Sophie M ^a   Begemann, Marieke J H ^a   Goverde, Angelique J ^a   Sommer, Iris E C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cognition; Meta analysis; Oxytocin; Schizophrenia; Sex hormones; Treatment

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; ETHINYLESTRADIOL; OXYTOCIN; PLACEBO; PRASTERONE; PREGNENOLONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TESTOSTERONE; NEUROLEPTIC AGENT; SEX HORMONE;

ABDOMINAL PAIN; AKATHISIA; ANOREXIA; ARTICLE; BREAST TENDERNESS; COGNITION; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; EFFECT SIZE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FEVER; HEADACHE; HUMAN; INSOMNIA; LETHARGY; MALAISE; MALE; MENSTRUAL IRREGULARITY; META ANALYSIS; MUSCULOSKELETAL STIFFNESS; NAUSEA; NOSE DISEASE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; QUANTITATIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS LEGS SYNDROME; RESTLESSNESS; SALIVATION; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLEEP DISORDER; SORE THROAT; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TINNITUS; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING; XEROSTOMIA; HORMONE SUBSTITUTION; PROCEDURES;

ANTIPSYCHOTIC AGENTS; GONADAL HORMONES; HORMONE REPLACEMENT THERAPY; HUMANS; OXYTOCIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84946480162     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.04.002     Document Type: Review

References (102)

1. Akhondzadeh S., Nejatisafa A.A., Amini H., Mohammadi M.R., Larijani B., Kashani L., Raisi F., Kamalipour A. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1007-1012.
2. Aleman A., Kahn R.S., Selten J.-P. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch. Gen. Psychiatry 2003, 60:565-571.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, (DSM-IV). Fourth edition.
4. Andreasen N. The Scale for the Assessment of Negative Symptoms (SANS) 1981, Iowa City University, Iowa.
5. Andreasen N. The Scale for the Assessment of Positive Symptoms (SAPS) 1984, Iowa City University, Iowa.
6. Begemann M.J.H., Dekker C.F., Van Lunenburg M., Sommer I.E. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr. Res. 2012, 141:179-184.
7. Beral V., Banks E., Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002, 360:942-944.
8. Bergemann N., Parzer P., Runnebaum B., Resch F., Mundt C. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol. Med. 2007, 37:1427-1436.
9. Borenstein M., Hedges L., Higgins J., Rothstein H. Comprehensive Meta Analysis Version 2 2005, Biostat Inc, Engelwood, NJ.
10. Borrow A.P., Cameron N.M. Estrogenic mediation of serotonergic and neurotrophic systems: implications for female mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 54:13-25.
11. Cacciotti-Saija C., Langdon R., Ward P.B., Hickie I.B., Scott E.M., Naismith S.L., Moore L., Alvares G.A., Redoblado Hodge M.A., Guastella A.J. A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis. Schizophr. Bull. 2014, 1-11.
12. Chakrabarti M., Haque A., Banik N.L., Nagarkatti P., Nagarkatti M., Ray S.K. Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration. Brain Res. Bull. 2014, 109C:22-31.
13. Cochran D.M., Fallon D., Hill M., Frazier J.A. The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings. Harv. Rev. Psychiatry 2014, 21:219-247.
14. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, NA.
15. Desai P.R., Lawson K.A., Barner J.C., Rascati K.L. Identifying patient characteristics associated with high schizophrenia-related direct medical costs in community-dwelling patients. J. Manag. Care Pharm. 2013, 19:468-477.
16. Dunlap W., Cortina J., Vaslow J., Burke M. Meta-analysis of experiments with matched groups or repeated measures designs. Psychol. Methods 1996, 1:170-177.
17. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
18. Elias A., Kumar A. Testosterone for schizophrenia. Cochrane Database Syst. Rev. 2007, CD006197.
19. Feifel D. Is oxytocin a promising treatment for schizophrenia?. Expert. Rev. Neurother. 2011, 11:157-159.
20. Feifel D., MacDonald K., Nguyen A., Cobb P., Warlan H., Galangue B., Minassian A., Becker O., Cooper J., Perry W., Lefebvre M., Gonzales J., Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 2010, 68:678-680.
21. Feifel D., MacDonald K., Cobb P., Minassian A. Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia. Schizophr. Res. 2012, 139:207-210.
22. Fervaha G., Foussias G., Agid O., Remington G. Impact of primary negative symptoms on functional outcomes in schizophrenia. Eur. Psychiatry 2014, 29:449-455.
23. Fink G., Sumner B.E., Mcqueen J.K., Wilson H., Rosie R. Sex steroid control of mood, mental state and memory. Clin. Exp. Pharmacol. Physiol. 1998, 25:764-775.
24. Frost K., Keller W., Buchanan R., Gold J., Koenig J., Ossenfort K., Katz A., Strauss G. Plasma oxytocin levels are associated with impaired social cognition and neurocognition in schizophrenia. Arch. Clin. Neuropsychol. 2014, 29:577-578.
25. Garcia-Segura L.M., Azcoitia I., Doncarlos L.L. Neuroprotection by estradiol. Prog. Neurobiol. 2001, 63:29-60.
26. Gattaz W.F., Vogel P., Riecher-Rössler A., Soddu G. Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biol. Psychiatry 1994, 36:137-139.
27. Ghafari E., Fararouie M., Shirazi H.G., Farhangfar A., Ghaderi F., Mohammadi A. Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia: a double-blind, randomized, placebo-controlled clinical trial. Clin. Schizophr. Relat. Psychoses 2013, 6:172-176.
28. Gibson C.M., Penn D.L., Smedley K.L., Leserman J., Elliott T., Pedersen C.A. A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia. Schizophr. Res. 2014, 156:261-265.
29. Gillies G.E., McArthur S. Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol. Rev. 2010, 62:155-198.
30. Gizzo S., Saccardi C., Patrelli T.S., Berretta R., Capobianco G., Di Gangi S., Vacilotto A., Bertocco A., Noventa M., Ancona E., D'Antona D., Nardelli G.B. Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications. Obstet. Gynecol. Surv. 2013, 68:467-481.
31. Goldman M., Marlow-O'Connor M., Torres I., Carter C.S. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr. Res. 2008, 98:247-255.
32. Goyal R.O., Sagar R., Ammini A.C., Khurana M.L., Alias A.G. Negative correlation between negative symptoms of schizophrenia and testosterone levels. Ann. N. Y. Acad. Sci. 2004, 1032:291-294.
33. Grigoriadis S., Seeman M.V. The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can. J. Psychiatry 2002, 47:437-442.
34. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003, 28(Suppl. 2):17-54.
35. Häfner H., Behrens S., De Vry J., Gattaz W.F. An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia. Psychiatry Res. 1991, 38:125-134.
36. Halbreich U., Kahn L.S. Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology 2003, 28(Suppl. 2):1-16.
37. Harris D.S., Wolkowitz O.M., Reus V.I. Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients. World J. Biol. Psychiatry 2001, 2:99-102.
38. Higgins J.P.T., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
39. Huber T.J., Tettenborn C., Leifke E., Emrich H.M. Sex hormones in psychotic men. Psychoneuroendocrinology 2005, 30:111-114.
40. Huerta-Ramos E., Iniesta R., Ochoa S., Cobo J., Miquel E., Roca M., Serrano-Blanco A., Teba F., Usall J. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Eur. Neuropsychopharmacol. 2014, 24:223-231.
41. Iager A.C., Kirch D.G., Wyatt R.J. A negative symptom rating scale. Psychiatry Res. 1985, 16:27-36.
42. Jockenhövel F. Testosterone supplementation: what and how to give. Aging Male 2003, 6:200-206.
43. Kaneda Y., Ohmori T. Relation between estradiol and negative symptoms in men with schizophrenia. J. Neuropsychiatry Clin. Neurosci. 2005, 17:239-242.
44. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
45. Kelley G.A., Kelley K.S. Statistical models for meta-analysis: a brief tutorial. World J. Methodol. 2012, 2:27-32.
46. Kianimehr G., Fatehi F., Hashempoor S., Khodaei-Ardakani M.-R., Rezaei F., Nazari A., Kashani L., Akhondzadeh S. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. Daru J. Pharm. Sci. 2014, 22:55.
47. Ko Y.-H., Jung S.-W., Joe S.-H., Lee C.-H., Jung H.-G., Jung I.-K., Kim S.-H., Lee M.-S. Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia. Psychoneuroendocrinology 2007, 32:385-391.
48. Ko Y.-H., Lew Y.-M., Jung S.-W., Joe S.-H., Lee C.-H., Jung H.-G., Lee M.-S. Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2008, 28:375-383.
49. Kontopantelis E., Springate D.A., Reeves D. A re-analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta-analyses. PLoS One 2013, 8:e69930.
50. Kreinin A., Bawakny N., Ritsner M.S. Adjunctive pregnenolone ameliorates the cognitive deficits in recent-onset schizophrenia. Clin. Schizophr. Relat. Psychoses 2014, 1-31.
51. Kulkarni J., Riedel A., de Castella A.R., Fitzgerald P.B., Rolfe T.J., Taffe J., Burger H. Estrogen-a potential treatment for schizophrenia. Schizophr. Res. 2001, 48:137-144.
52. Kulkarni J., de Castella A., Fitzgerald P.B., Gurvich C.T., Bailey M., Bartholomeusz C., Burger H. Estrogen in severe mental illness: a potential new treatment approach. Arch. Gen. Psychiatry 2008, 65:955-960.
53. Kulkarni J., Gurvich C., Lee S.J., Gilbert H., Gavrilidis E., de Castella A., Berk M., Dodd S., Fitzgerald P.B., Davis S.R. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 2010, 35:1142-1147.
54. Kulkarni J., De Castella A., Headey B., Marston N., Sinclair K., Lee S., Gurvich C., Fitzgerald P.B., Burger H. Estrogens and men with schizophrenia: is there a case for adjunctive therapy?. Schizophr. Res. 2011, 125:278-283.
55. Kulkarni J., Gavrilidis E., Wang W., Worsley R., Fitzgerald P.B., Gurvich C., Van Rheenen T., Berk M., Burger H. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol. Psychiatry 2014, 1-8.
56. Lee H.-J., Macbeth A.H., Pagani J.H., Young W.S. Oxytocin: the great facilitator of life. Prog. Neurobiol. 2009, 88:127-151.
57. Lee M.R., Wehring H.J., Mcmahon R.P., Linthicum J., Cascella N., Liu F., Bellack A., Buchanan R.W., Strauss G.P., Contoreggi C., Kelly D.L. Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study. Schizophr. Res. 2013, 145:110-115.
58. Lepage M., Bodnar M., Bowie C.R. Neurocognition: clinical and functional outcomes in schizophrenia. Can. J. Psychiatry 2014, 59:5-12.
59. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P.A., Clarke M., Devereaux P.J., Kleijnen J., Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J. Clin. Epidemiol. 2009, 62:e1-e34.
60. Lipsey M.W., Wilson D.B. Practical Meta-analysis 2001, Sage, Thousand Oaks, CA.
61. Louzã M.R., Marques A.P., Elkis H., Bassitt D., Diegoli M., Gattaz W.F. Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophr. Res. 2004, 66:97-100.
62. Mai J.K., Berger K., Sofroniew M.V. Morphometric evaluation of neurophysin-immunoreactivity in the human brain: pronounced inter-individual variability and evidence for altered staining patterns in schizophrenia. J. Hirnforsch. 1993, 34:133-154.
63. Maninger N., Wolkowitz O.M., Reus V.I., Epel E.S., Mellon S.H. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front. Neuroendocrinol. 2009, 30:65-91.
64. Marjoribanks J., Farquhar C., Roberts H., Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev. 2012, 7:CD004143.
65. Marx C.E., Trost W., Shampine L., Lieberman J., Morrow A., Thakore J. Neuroactive steroids in schizophrenia: relevance to symptoms and therapeutics. Biol. Psychiatry 2004, 55:171.
66. Marx C.E., Keefe R.S.E., Buchanan R.W., Hamer R.M., Kilts J.D., Bradford D.W., Strauss J.L., Naylor J.C., Payne V.M., Lieberman J.A., Savitz A.J., Leimone L.A., Dunn L., Porcu P., Morrow A.L., Shampine L.J. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 2009, 34:1885-1903.
67. Marx C.E., Lee J., Subramaniam M., Rapisarda A., Bautista D.C.T., Chan E., Kilts J.D., Buchanan R.W., Wai E.P., Verma S., Sim K., Hariram J., Jacob R., Keefe R.S.E., Chong S.A. Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology (Berlin) 2014, 231:3647-3662.
68. Maximov P.Y., Lee T.M., Jordan V.C. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr. Clin. Pharmacol. 2013, 8:135-155.
69. Mellon S.H. Neurosteroid regulation of central nervous system development. Pharmacol. Ther. 2007, 116:107-124.
70. Modabbernia A., Rezaei F., Salehi B., Jafarinia M., Ashrafi M., Tabrizi M., Hosseini S.M.R., Tajdini M., Ghaleiha A., Akhondzadeh S. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs 2013, 27:57-65.
71. Moore L., Kyaw M., Vercammen A., Lenroot R., Kulkarni J., Curtis J., O'Donnell M., Carr V.J., Shannon Weickert C., Weickert T.W. Serum testosterone levels are related to cognitive function in men with schizophrenia. Psychoneuroendocrinology 2013, 38:1717-1728.
72. Nachshoni T., Ebert T., Abramovitch Y., Assael-Amir M., Kotler M., Maayan R., Weizman A., Strous R.D. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Schizophr. Res. 2005, 79:251-256.
73. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962, 10:799-812.
74. Pedersen C.A., Gibson C.M., Rau S.W., Salimi K., Smedley K.L., Casey R.L., Leserman J., Jarskog L.F., Penn D.L. Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia. Schizophr. Res. 2011, 132:50-53.
75. Riecher-Rössler A., Häfner H. Schizophrenia and oestrogens-is there an association?. Eur. Arch. Psychiatry Clin. Neurosci. 1993, 242:323-328.
76. Riecher-Rössler A., Häfner H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr. Scand. Suppl. 2000, 102:58-62.
77. Riecher-Rössler A., Häfner H., Stumbaum M., Maurer K., Schmidt R. Can estradiol modulate schizophrenic symptomatology?. Schizophr. Bull. 1994, 20:203-214.
78. Ritsner M.S. Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials. CNS Neurosci. Ther. 2010, 16:32-44.
79. Ritsner M.S., Gibel A., Ram E., Maayan R., Weizman A. Alterations in DHEA metabolism in schizophrenia: two-month case-control study. Eur. Neuropsychopharmacol. 2006, 16:137-146.
80. Ritsner M.S., Gibel A., Ratner Y., Tsinovoy G., Strous R.D. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J. Clin. Psychopharmacol. 2006, 26:495-499.
81. Ritsner M.S., Maayan R., Gibel A., Weizman A. Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects. Eur. Neuropsychopharmacol. 2007, 17:358-365.
82. Ritsner M., Gibel A., Ratner Y., Weizman A. Dehydroepiandrosterone and pregnenolone alterations in schizophrenia. Neuroactive Steroids in Brain Function, Behavior and Neuropsychiatric Disorders: Novel Strategies for Research and Treatment 2008, 251-298. Springer Science & Business Media, Bazel, Belgium. M.S. Ritsner, A. Weizman (Eds.).
83. Ritsner M.S., Gibel A., Shleifer T., Boguslavsky I., Zayed A., Maayan R., Weizman A., Lerner V. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J. Clin. Psychiatry 2010, 71:1351-1362.
84. Ritsner M.S., Bawakny H., Kreinin A. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial. Psychiatry Clin. Neurosci. 2014, 68:432-440.
85. Rosenthal R. The "file drawer problem " and tolerance for null results. Psychol. Bull. 1979, 86:638-641.
86. Rubin L.H., Carter C.S., Drogos L., Pournajafi-Nazarloo H., Sweeney J.A., Maki P.M. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr. Res. 2010, 124:13-21.
87. Sasayama D., Hattori K., Teraishi T., Hori H., Ota M., Yoshida S., Arima K., Higuchi T., Amano N., Kunugi H. Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia. Schizophr. Res. 2012, 139:201-206.
88. Schreihofer D.A., Ma Y. Estrogen receptors and ischemic neuroprotection: who, what, where, and when?. Brain Res. 2013, 1514:107-122.
89. Shadish W., Haddock C. Combining estimates of effect size. Handb. Res. Synth. Cooper H 1994, 261-281.
90. Shirayama Y., Hashimoto K., Suzuki Y., Higuchi T. Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia. Schizophr. Res. 2002, 58:69-74.
91. Sibbald B., Roberts C. Understanding controlled trials. Crossover trials. BMJ 1998, 316:1719.
92. Sisek-Šprem M., Križaj A., Jukić V., Milošević M., Petrović Z., Herceg M. Testosterone levels and clinical features of schizophrenia with emphasis on negative symptoms and aggression. Nord. J. Psychiatry 2014, 1-8.
93. Slotema C.W., Aleman A., Daskalakis Z.J., Sommer I.E. Meta-analysis of repetitive transcranial magnetic stimulation in the treatment of auditory verbal hallucinations: update and effects after one month. Schizophr. Res. 2012, 142:40-45.
94. Stanczyk F.Z. Measurement of androgens in women. Semin. Reprod. Med. 2006, 24:78-85.
95. Strous R.D., Maayan R., Lapidus R., Stryjer R., Lustig M., Kotler M., Weizman A. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch. Gen. Psychiatry 2003, 60:133-141.
96. Strous R.D., Stryjer R., Maayan R., Gal G., Viglin D., Katz E., Eisner D., Weizman A. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology 2007, 32:96-105.
97. Taherianfard M., Shariaty M. Evaluation of serum steroid hormones in schizophrenic patients. Indian J. Med. Sci. 2004, 58:3-9.
98. Usall J., Huerta-Ramos E., Iniesta R., Cobo J., Araya S., Roca M., Serrano-Blanco A., Teba F., Ochoa S. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J. Clin. Psychiatry 2011, 72:1552-1557.
99. Van Rijn S., Aleman A., De Sonneville L., Sprong M., Ziermans T., Schothorst P., van Engeland H., Swaab H. Neuroendocrine markers of high risk for psychosis: salivary testosterone in adolescent boys with prodromal symptoms. Psychol. Med. 2011, 41:1815-1822.
100. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., Bevers T.B., Fehrenbacher L., Pajon E.R., Wade J.L., Robidoux A., Margolese R.G., James J., Runowicz C.D., Ganz P.A., Reis S.E., McCaskill-Stevens W., Ford L.G., Jordan V.C., Wolmark N. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev. Res. 2010, 3:696-706.
101. World Health Organization The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines 1992, WHO Press, Geneva.
102. Yaffe K., Krueger K., Cummings S.R., Blackwell T., Henderson V.W., Sarkar S., Ensrud K., Grady D. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am. J. Psychiatry 2005, 162:683-690.